Time-kill curves of daptomycin and Monte Carlo simulation for the treatment of bacteraemia caused by Enterococcus faecium.


Journal

Brazilian journal of microbiology : [publication of the Brazilian Society for Microbiology]
ISSN: 1678-4405
Titre abrégé: Braz J Microbiol
Pays: Brazil
ID NLM: 101095924

Informations de publication

Date de publication:
Mar 2020
Historique:
received: 26 12 2018
accepted: 22 11 2019
pubmed: 18 12 2019
medline: 11 11 2020
entrez: 18 12 2019
Statut: ppublish

Résumé

The aim of this study was to investigate the effect of daptomycin against vancomycin-resistant Enterococcus faecium bacteraemia using computer modelling. Data obtained in vitro from time-kill curves were evaluated by PK/PD modelling and Monte Carlo simulations to determine the logarithmic reduction in the number of colony-forming units (CFU)/mL over 18 days of daptomycin treatment at 6, 8, and 10 mg/kg doses every 24 or 48 h and with variations in creatinine clearance (CL Static time-kill model was employed to investigate the antibacterial efficacy of constant daptomycin concentrations. The time-kill curve analysis was performed using mathematical modelling based on a Hill coefficient factor. There was an expressive reduction (> 2 Log CFU/mL) over 18 days of daptomycin treatment in 75th percentile of individuals with CL Higher daptomycin doses were associated with higher mortality in time-kill curves. The simulations indicated that independent of the CL

Identifiants

pubmed: 31845296
doi: 10.1007/s42770-019-00200-4
pii: 10.1007/s42770-019-00200-4
pmc: PMC7058735
doi:

Substances chimiques

Daptomycin NWQ5N31VKK

Types de publication

Journal Article

Langues

eng

Sous-ensembles de citation

IM

Pagination

169-176

Références

Diagn Microbiol Infect Dis. 2014 Apr;78(4):429-36
pubmed: 24440509
Drug Discov Today Technol. 2016 Sep - Dec;21-22:41-49
pubmed: 27978987
Nat Rev Microbiol. 2012 Mar 16;10(4):266-78
pubmed: 22421879
J Antimicrob Chemother. 2010 Jun;65(6):1126-36
pubmed: 20363805
Antimicrob Agents Chemother. 2006 Oct;50(10):3245-9
pubmed: 17005801
Clin Microbiol Rev. 2014 Oct;27(4):647-64
pubmed: 25278570
Pharmacology. 2008;81(2):79-91
pubmed: 17940348
Clin Infect Dis. 2017 Apr 15;64(8):1026-1034
pubmed: 28329222
Adv Ther. 2015 Dec;32(12):1192-205
pubmed: 26610384
Clin Ther. 2010 Sep;32(10):1713-9
pubmed: 21194593
Antimicrob Agents Chemother. 2011 Oct;55(10):4619-30
pubmed: 21807983
Infect Dis (Lond). 2015;47(12):846-51
pubmed: 26167850
Infect Control Hosp Epidemiol. 2013 Jan;34(1):1-14
pubmed: 23221186
J Antimicrob Chemother. 2011 Sep;66(9):2112-8
pubmed: 21697178
Int J Antimicrob Agents. 2013 Sep;42(3):202-10
pubmed: 23845504
Int J Antimicrob Agents. 2013 Sep;42(3):250-5
pubmed: 23891432
J Pharmacokinet Pharmacodyn. 2007 Dec;34(6):727-51
pubmed: 17906920
J Antimicrob Chemother. 2017 Aug 1;72(8):2342-2350
pubmed: 28575511
Future Microbiol. 2006 Oct;1(3):255-65
pubmed: 17661638
J Antimicrob Chemother. 2005 May;55(5):601-7
pubmed: 15772142
Pharmacol Rev. 2013 Jun 26;65(3):1053-90
pubmed: 23803529
Clin Infect Dis. 2004 Jun 15;38(12):1673-81
pubmed: 15227611
Antimicrob Agents Chemother. 2018 Sep 24;62(10):
pubmed: 30012755
Antimicrob Agents Chemother. 2012 Nov;56(11):5626-32
pubmed: 22908174
J Antimicrob Chemother. 2007 Aug;60(2):334-40
pubmed: 17540670
Clin Infect Dis. 2016 Jun 15;62(12):1514-1520
pubmed: 27045126
Infect Drug Resist. 2015 Jul 24;8:217-30
pubmed: 26244026
Int J Antimicrob Agents. 2007 Mar;29(3):263-70
pubmed: 17194570
Clin Ther. 2016 Nov;38(11):2468-2476
pubmed: 27771176
Eur J Med Res. 2010 Nov 30;15(12):533-43
pubmed: 21163728
Curr Opin Microbiol. 2000 Oct;3(5):515-21
pubmed: 11050452
Antimicrob Agents Chemother. 2013 Sep;57(9):4190-6
pubmed: 23774437
Ann Pharmacother. 2009 Jul;43(7):1211-9
pubmed: 19584384

Auteurs

Bruna Kochhann Menezes (BK)

Health Sciences Graduate Program, University of Caxias do Sul, Caxias do Sul, Brazil.

Izabel Almeida Alves (IA)

Pharmaceutical Sciences Graduate Program, Federal University of Rio Grande do Sul, Porto Alegre, Brazil.

Keli Jaqueline Staudt (KJ)

Medical Sciences Graduate Program, Federal University of Rio Grande do Sul, Porto Alegre, Brazil.

Betina Montanari Beltrame (BM)

College of Pharmacy, University of Caxias do Sul, Caxias do Sul, Brazil.

Letícia Venz (L)

College of Pharmacy, University of Caxias do Sul, Caxias do Sul, Brazil.

Lessandra Michelin (L)

College of Pharmacy, University of Caxias do Sul, Caxias do Sul, Brazil.

Bibiana Verlindo Araujo (BV)

College of Pharmacy, Federal University of Rio Grande do Sul, Porto Alegre, Brazil.

Leandro Tasso (L)

Health Sciences Graduate Program, University of Caxias do Sul, Caxias do Sul, Brazil. ltasso@ucs.br.

Articles similaires

[Redispensing of expensive oral anticancer medicines: a practical application].

Lisanne N van Merendonk, Kübra Akgöl, Bastiaan Nuijen
1.00
Humans Antineoplastic Agents Administration, Oral Drug Costs Counterfeit Drugs

Smoking Cessation and Incident Cardiovascular Disease.

Jun Hwan Cho, Seung Yong Shin, Hoseob Kim et al.
1.00
Humans Male Smoking Cessation Cardiovascular Diseases Female
Humans United States Aged Cross-Sectional Studies Medicare Part C
1.00
Humans Yoga Low Back Pain Female Male

Classifications MeSH